Brief: Citius Pharmaceuticals Reports FY2023 Financial Results
02/01/2024 13:34
Jan 2 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS, INC. REPORTS FISCAL FULL YEAR 2023
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* SAYS ESTIMATES THAT ITS AVAILABLE CASH RESOURCES WILL BE
SUFFICIENT TO FUND ITS OPERATIONS THROUGH AUGUST 2024
* MINO-LOK(®) PIVOTAL PHASE 3 TRIAL ENROLLMENT COMPLETED;
TOPLINE
DATA EXPECTED 2Q 2024
* LYMPHIR BLA RESUBMISSION ON TRACK FOR EARLY 2024
Source text for Eikon: ID:nPn8bkjKFa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules